Phosphodiesterase-4 as a therapeutic target

被引：521

作者：

Houslay, MD

Schafer, P

Zhang, KYJ

机构：

[1] Univ Glasgow, Div Biochem & Mol Biol, IBLS, Glasgow G12 8QQ, Lanark, Scotland

[2] Celgene, Drug Discovery Dept, Immunotherapeut Div, Summit, NJ 07901 USA

[3] Plexxikon, Dept Biol Struct, Berkeley, CA 94710 USA

来源：

DRUG DISCOVERY TODAY | 2005年 / 10卷 / 22期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1016/S1359-6446(05)03622-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cyclic AMP (CAMP) is a key second messenger in all cells. It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degradation. Underpinning compartmentalized CAMP signaling are similar to 20 members of the phosphodiesterase-4 (PDE4) family. The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers. Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biology and related preclinical and clinical pharmacology.

引用

收藏

页码：1503 / 1519

页数：17

相关论文

共 121 条

[31] Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production [J].

Eigler, A ;

Siegmund, B ;

Emmerich, U ;

Baumann, KH ;

Hartmann, G ;

Endres, S .

JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (01) :101-107

[32] BRAIN DISTRIBUTION OF 4 RAT HOMOLOGS OF THE DROSOPHILA DUNCE CAMP-PHOSPHODIESTERASE [J].

ENGELS, P ;

ABDELAL, S ;

HULLEY, P ;

LUBBERT, H .

JOURNAL OF NEUROSCIENCE RESEARCH, 1995, 41 (02) :169-178

[33]

ESSAYAN DM, 1994, J IMMUNOL, V153, P3408

[34] Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4 [J].

Favot, L ;

Keravis, T ;

Lugnier, C .

THROMBOSIS AND HAEMOSTASIS, 2004, 92 (03) :634-645

[35] PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration [J].

Fleming, YM ;

Frame, MC ;

Houslay, MD .

JOURNAL OF CELL SCIENCE, 2004, 117 (11) :2377-2388

[36] Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis [J].

Hanifin, JM ;

Chan, SC ;

Cheng, JB ;

Tofte, SJ ;

Henderson, WR ;

Kirby, DS ;

Weiner, ES .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (01) :51-56

[37] Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D [J].

Hansen, G ;

Jin, SLC ;

Umetsu, DT ;

Conti, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6751-6756

[38] cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model [J].

Hoffmann, R ;

Wilkinson, IR ;

McCallum, JF ;

Engels, P ;

Houslay, MD .

BIOCHEMICAL JOURNAL, 1998, 333 :139-149

[39] The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579 [J].

Hoffmann, R ;

Baillie, GS ;

MacKenzie, SJ ;

Yarwood, SJ ;

Houslay, MD .

EMBO JOURNAL, 1999, 18 (04) :893-903

[40] Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling [J].

Houslay, MD ;

Kolch, W .

MOLECULAR PHARMACOLOGY, 2000, 58 (04) :659-668

← 1 2 3 4 5 6 7 8 9 10 →